Midazolam
- Generic Name
- Midazolam
- Brand Names
- Buccolam, Busulfex, Nayzilam, Seizalam
- Drug Type
- Small Molecule
- Chemical Formula
- C18H13ClFN3
- CAS Number
- 59467-70-8
- Unique Ingredient Identifier
- R60L0SM5BC
- Background
Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called benzodiazepines. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal...
- Indication
Midazolam has different indications depending on its formulation by the FDA.
Nasal
...
- Associated Conditions
- Epileptic seizure, Status Epilepticus
- Associated Therapies
- Anaesthesia, Anxiolytic therapy therapy, Sedation for mechanically-ventilated patients, Preoperative amnesia therapy, Preoperative sedation therapy
Evaluation of Renal Protection Of Dexmedetomidine Versus Midazolam As a Sedative For Septic Patients In Intensive Care Unit
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Minia University
- Target Recruit Count
- 40
- Registration Number
- NCT05903963
- Locations
- 🇪🇬
Marlin Zarif Shehata, Minya, Egypt
A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 65
- Registration Number
- NCT05901714
- Locations
- 🇺🇸
Local Institution - 0001, Miami, Florida, United States
A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT05895266
- Locations
- 🇺🇸
Acpru /Id# 254970, Grayslake, Illinois, United States
Remimazolam for Postoperative Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- Yangzhou University
- Target Recruit Count
- 50
- Registration Number
- NCT05891145
- Locations
- 🇨🇳
The Affiliated Hospital of Yangzhou University., Yangzhou, Jiangsu, China
Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 21
- Registration Number
- NCT05891119
- Locations
- 🇺🇸
Direct Helpers Research Center (DHRC), Hialeah, Florida, United States
🇺🇸Velocity Clinical Research -Spartanburg, Spartanburg, South Carolina, United States
🇺🇸DermDox Dermatology Centers, PC - Sugarloaf, Nashville, Tennessee, United States
Synaptic Imaging and Network Activity in Treatment Resistant Depression
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- King's College London
- Target Recruit Count
- 56
- Registration Number
- NCT05870501
- Locations
- 🇬🇧
The Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom
A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 30
- Registration Number
- NCT05866055
- Locations
- 🇬🇧
PAREXEL International, Harrow, United Kingdom
A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 18
- Registration Number
- NCT05852769
- Locations
- 🇺🇸
ICON plc, Millcreek, Utah, United States
A Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 144
- Registration Number
- NCT05840952
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
Remimazolam Versus Midaszolam for Sedation in Diagnostic Upper Gastrointestinal Endoscopy
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 132
- Registration Number
- NCT05836545
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.